Meet Our Staff & Leadership Experts
ILE LEADERSHIP TEAM
Joseph Shaw COO
A senior executive with extensive experience in the Life Science Industry.
Specializations in domestic and international Life Science technologies commercialization include pharmaceuticals, immunoassays, nanotechnology, medical devices, vaccines, and genomic products.
A history of significant accomplishments in biotech development, clinical evolvement, and associated regulatory issues. This experience combines extensive market expertise and corporate development in Canada, Europe, Asia, and North and South America. He has extensive skill in building talented and successful teams in start-ups and mature mid-sized organizations needing restructuring while formulating winning corporate strategies and tactics for marketing, R&D, manufacturing, financing, strategic partnerships, and regulatory issues.
Mr. Shaw is a frequent speaker at International forums on biotechnology development and start-up companies and has taught at various academic institutions in Canada, Australia, and the United States. Mr. Shaw had held CEO positions in private and publicly traded companies in Italy, Canada, the United States, and Australia, with technologies ranging from diagnostics to pharmaceuticals and vaccines. He founded International Life Science Enterprises (ILSE) to utilize his domestic U.S. and international expertise to expand Life Science companies' global outreach. He would be pleased to discuss your international strategies with you and determine if ILSE can assist you in achieving your goals – please call him.
Nida Shoubash CEO
Ms. Shoubash has supervisory and "hands-on" experience as a founder of entrepreneurial organizations. She recently graduated Phi Beta Kappa with a degree in Multi-cultural Human Resources. She is a native of the Middle East and is the Middle East specialist for the ILE program. Ms. Shoubash brings the group over a decade of entrepreneurial experience and a firm grasp of diverse cultural knowledge.
Sandra Lobo Advisor
Biotechnology / Biochemistry / R&D / Molecular and Cell Biology / DNA Cloning / Start-ups/Vaccines / Investor & Scientific Relations / Funding & Grant Writing / Product Development & Launch
A skilled scientist with extensive experience developing, commercializing, and launching new drugs, vaccines, and medical device technologies. Ms. Lobo's research has provided strategic direction for companies in bio-engineering, gene cloning, human and animal vaccines, and pharmaceuticals. She is equally adept in the purification/characterization of proteins and enzymes, bioassay and enzyme assay development, and analytical instrumentation.
Ms. Lobo has a Ph.D. in Biomedicinal Chemistry from the School of Pharmacy – University of Maryland and an M.S. in Pharmacy with a major in Pharmacognosy from Prin. K.M. Kundnani College of Pharmacy – University of Bombay, and a B.S. in Pharmacy, Pharmaceutical Sciences from Poona College of Pharmacy – University of Poona, India.
Sandra is a sought-after speaker, having presented and authored numerous papers and reviews for critical scientific/medical journals.
Timothy Tripp Advisor
Tim Tripp, MS, MBA, was the Director of the Biotechnology Resource Center (BRC) and the Biotechnology Institute (BTI) Assistant Director at the University of Minnesota. In the BRC, he provided contract biotechnology and fermentation services to industry and academia. In the BTI, he is part of the top administration of a world-class research institute in biotechnology. Before attending the University of Minnesota, Tim was the vice president of corporate development, a scientist, and a program manager at Syntiron LLC, a vaccine research and development company in St. Paul, MN. Tim managed a 4.2 million dollar Defense Threat Reduction Agency Research Contract developing biodefense vaccines here. In addition, Tim has worked for various private and publicly traded pharmaceutical/medical device manufacturers, providing product development, fermentation expertise, and downstream process development for products for human use. Before this, he gained experience in a gram-positive pathogenesis research laboratory, where he developed expertise in animal models, molecular biology, and select agents. He has co-authored 15 peer-reviewed journal articles on various aspects of staphylococcus, streptococcus, and enterococcus pathogenesis.
Hiroshi Matsushima Advisor
A resisent of Japan Matsushsima san prvices support for ILSE’s Japanese clientele. A Kyoto University of Foreign Studies graduate and a Bachelor of English degree. Over 15 Years of Sales, Product Development and Marketing in the Automotive, Medical and Dental fields. He has expertise in coordinating Global Sales Activities in the European Union, Asia, and the United States. His expertise is in medical metallurgical materials, where he has interacted with major global medical device organisations.
Colin W. Dykes, PhD Advisor
Colin comes from a background in molecular biology and genetics. He established Glaxo's (now GSK) UK-based human genetics and genomics programs during the mid-90s, resulting in the identification of mutations involved in susceptibility to migraine and psoriasis and contributing to the discovery of the presenilin-1 gene's involvement in early-onset Alzheimer's disease. After moving to Variagenics Inc, a Cambridge, MA-based pharmacogenomics company in 1998, as V.P. Research, Dr. Dykes headed programs to develop DNA markers linked to drug response, using high-throughput sequencing to identify polymorphisms in pathways involved in drug efficacy and toxicity. After Variagenics' successful IPO in 2000, Dr. Dykes subsequently accepted a position as Chief Scientific Officer at OpGen Inc. to commercialize Optical Mapping, a novel single-molecule DNA technology, used in genome sequencing and microbial strain characterization, including epidemiological analysis of disease outbreaks such as the 2011 E. coli 0157 outbreak in Germany. Most recently, he served as Chief Scientific Officer of nanoMR Inc., an early-stage company developing an immunomagnetic capture system to identify bloodstream infections rapidly. The system will form the basis of a diagnostic product for the Clinical Microbiology and Food Safety markets. Dr Dykes obtained his PhD from Cardiff University and performed post-doctoral research at Vanderbilt University School of Medicine before joining Glaxo.